These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37811547)

  • 1. Structure-based virtual screening and fragment replacement to design novel inhibitors of Coxsackievirus A16 (CVA16).
    Zhou J; Zhao Y; Yang R; Zhang Z; Jin Y; Wang L; Huang M
    J Biomol Struct Dyn; 2023 Oct; ():1-13. PubMed ID: 37811547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecules targeting coxsackievirus A16 capsid inactivate viral particles and prevent viral binding.
    Lin CJ; Liu CH; Wang JY; Lin CC; Li YF; Richardson CD; Lin LT
    Emerg Microbes Infect; 2018 Sep; 7(1):162. PubMed ID: 30254193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
    Lyu K; He YL; Li HY; Chen R
    J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure Elucidation of Coxsackievirus A16 in Complex with GPP3 Informs a Systematic Review of Highly Potent Capsid Binders to Enteroviruses.
    De Colibus L; Wang X; Tijsma A; Neyts J; Spyrou JA; Ren J; Grimes JM; Puerstinger G; Leyssen P; Fry EE; Rao Z; Stuart DI
    PLoS Pathog; 2015 Oct; 11(10):e1005165. PubMed ID: 26485389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
    Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
    Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of cell surface glycosaminoglycans in chebulagic acid's and punicalagin's antiviral activities against Coxsackievirus A16 infection.
    Liu CH; Kuo YT; Lin CJ; Lin LT
    Phytomedicine; 2023 Nov; 120():155047. PubMed ID: 37690230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coxsackievirus A16 in Southern Vietnam.
    Nhu LNT; Nhan LNT; Anh NT; Hong NTT; Van HMT; Thanh TT; Hang VTT; Han DDK; Ny NTH; Nguyet LA; Quy DT; Qui PT; Khanh TH; Hung NT; Tuan HM; Chau NVV; Thwaites G; van Doorn HR; Tan LV
    Front Microbiol; 2021; 12():689658. PubMed ID: 34248913
    [No Abstract]   [Full Text] [Related]  

  • 8. Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.
    Ren J; Wang X; Zhu L; Hu Z; Gao Q; Yang P; Li X; Wang J; Shen X; Fry EE; Rao Z; Stuart DI
    J Virol; 2015 Oct; 89(20):10500-11. PubMed ID: 26269176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete sequence analysis and antiviral screening of medicinal plants for human coxsackievirus a16 isolated in Korea.
    Song JH; Park K; Shim A; Kwon BE; Ahn JH; Choi YJ; Kim JK; Yeo SG; Yoon K; Ko HJ
    Osong Public Health Res Perspect; 2015 Feb; 6(1):52-8. PubMed ID: 25737832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16.
    Kelly JT; De Colibus L; Elliott L; Fry EE; Stuart DI; Rowlands DJ; Stonehouse NJ
    Antiviral Res; 2015 Dec; 124():77-82. PubMed ID: 26522770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.
    Sun YS; Xia Y; Xu F; Lu HJ; Mao ZA; Gao M; Pan TY; Yao PP; Wang Z; Zhu HP
    Emerg Microbes Infect; 2022 Dec; 11(1):1994-2006. PubMed ID: 35787233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic characteristics of the P1 coding region of Coxsackievirus A16 associated with hand, foot, and mouth disease in China.
    Xu L; Cui D; Wang L; Cheng J; Sun C; Li L; Cao H
    Mol Biol Rep; 2018 Dec; 45(6):1947-1955. PubMed ID: 30182173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and Cross Neutralization Analyses of Coxsackievirus A16 Circulating in Taiwan from 1998 to 2021 Suggest Dominant Genotype B1 can Serve as Vaccine Candidate.
    Cheng D; Chiu YW; Huang SW; Lien YY; Chang CL; Tsai HP; Wang YF; Wang JR
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology of coxsackievirus A16 circulating in children in Beijing, China from 2010 to 2019.
    Hu YF; Jia LP; Yu FY; Liu LY; Song QW; Dong HJ; Deng J; Qian Y; Zhao LQ; Deng L; Huang H; Zhu RN
    World J Pediatr; 2021 Oct; 17(5):508-516. PubMed ID: 34453285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research advances in molecular epidemiology and vaccines of Coxsackievirus A16].
    Chen XP; Tan XJ; Xu WB
    Bing Du Xue Bao; 2014 Jul; 30(4):483-8. PubMed ID: 25272607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of hand, foot, and mouth disease and the genetic characteristics of Coxsackievirus A16 in Taiyuan, Shanxi, China from 2010 to 2021.
    Guo J; Cao Z; Liu H; Xu J; Zhao L; Gao L; Zuo Z; Song Y; Han Z; Zhang Y; Wang J
    Front Cell Infect Microbiol; 2022; 12():1040414. PubMed ID: 36439232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease.
    Wang J; Chen X; Wang W; Zhang Y; Yang Z; Jin Y; Ge HM; Li E; Yang G
    J Ethnopharmacol; 2013 May; 147(1):114-21. PubMed ID: 23454684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
    Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
    Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I Interferons Triggered through the Toll-Like Receptor 3-TRIF Pathway Control Coxsackievirus A16 Infection in Young Mice.
    Yang J; Yang C; Guo N; Zhu K; Luo K; Zhang N; Zhao H; Cui Y; Chen L; Wang H; Gu J; Ge B; Qin CF; Leng Q
    J Virol; 2015 Nov; 89(21):10860-7. PubMed ID: 26292317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells.
    Somasundaram B; Chang C; Fan YY; Lim PY; Cardosa J; Lua L
    Methods; 2016 Feb; 95():38-45. PubMed ID: 26410190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.